No CrossRef data available.
Article contents
Risperidona en el tratamiento de la agitación y la agresión asociadas con trastornos psiquiátricos
Published online by Cambridge University Press: 12 May 2020
Resumen
Esta revisión proporciona una panorámica general de la prevalencia y el tratamiento de la agitación y la agresión, y se centra en el uso de la risperidona para tratar estos síntomas en pacientes de grupos de edad diferentes.
Metodos
Se utilizaron las bases de datos MEDLINE® y EMBASE® para identificar estudios controlados de risperidona en el tratamiento de los trastornos de comportamiento perturbador y los trastornos generalizados del desarrollo en pacientes pediátricos, la agitación aguda o la agresión en adultos y los síntomas psicológicos y conductuales de la demencia en los ancianos. Ademá, se consideraron ensayos clave al; descubierto a largo plazo que evaluaban la eficacia y la seguridad de la risperidona.
Resultados
Los resultados de los 19 estudios doble ciego identificados mostraban que la risperidona es eficaz en el tratamiento de la agitación y la agresion en las diferentes poblaciones, con independencia de la edad. La seguridad y la tolerabilidad de la risperidona parecen ser buenas en conjunto, pero se resaltaba algunas cuestiones de seguridad, como un riesgo más alto de acontecimientos adversos cerebro-vasculares en los ancianos con demencia.
Conclusiones
La risperidona es ύtil para tratar la agresión y la agitación asociadas con diversos trastornos psiquiatricos en pacientes de grupos de edad diferentes.
- Type
- Revisión
- Information
- Copyright
- Copyright © European Psychiatric Association 2006
References
Swann, AC. Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 2003;64(Suppl 4):26–35.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed., text revision. Washington, DC: American Psychiatric Publishing Inc.; 2000.Google Scholar
Angold, AErkanli, AFarmer, EMFairbank, JABums, BJKeeler, G, et al.Psychiatric disorder, impairment, and Service use in rural African American and white youth. Arch Gen Psychiatry 2002;59:893–901.CrossRefGoogle ScholarPubMed
Emerson, E. Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intellect Disabil Res 2003;47(Pt l):51–8.CrossRefGoogle ScholarPubMed
Barlow, KGrenyer, BIlkiw-Lavalle, O. Prevalence and precipitants of aggression in psychiatric inpatient units. Aust N Z J Psychiatry 2000;34:967–74.CrossRefGoogle ScholarPubMed
Grassi, LPeron, LMarangoni, CZanchi, PVanni, A. Characteristics of violent behaviour in acute psychiatric in-patients: a 5-year Italian study. Acta Psychiatr Scand 2001;104:273–9.CrossRefGoogle ScholarPubMed
Binder, RLMcNiel, DE. Effects of diagnosis and context on dangerous-ness. Am J Psychiatry 1988;145(6):728–32.Google Scholar
Swanson, JW. Mental disorder, substance abuse and community violence: an epidemiological approach. In: Monaban, JSteadman, HJ, editors. In violence and mental disorder: developments in risk assessment. Chicago: The University of Chicag Press; 1994. p 101–136.Google Scholar
Lyketsos, CGSteinberg, MTschanz, JTNorton, MCSteffens, DCBreitner, JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708–14.CrossRefGoogle Scholar
Lyketsos, CGLopez, OJones, BFitzpatrick, ALBreitner, JDeKosky, S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;228:1475–83.CrossRefGoogle Scholar
Chan, DCKasper, JDBlack, BSRabins, PV. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int J Geriatr Psychiatry 2003;18:174–82.CrossRefGoogle ScholarPubMed
Margallo-Lana, MSwann, AO'Brien, JFairbaim, AReichelt, KPotkins, D, et al.Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001;16:39–44.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Jeste, DVFinkel, SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;8:29–34.CrossRefGoogle ScholarPubMed
Renouf, AGKovacs, MMukerji, P. Relationship of depressive, conduct, and comorbid disorders and social functioning in childhood. J Am Acad Child Adolesc Psychiatry 1997;36:998–1004.CrossRefGoogle ScholarPubMed
Schaeffer, CMPetras, HIalongo, NPoduska, JKellam, S. Modeling growth in boys’ aggressive behavior across elementary school: links to later criminal involvement, conduct disorder, and antisocial personality disorder. Dev Psychol 2003;39:1020–35.CrossRefGoogle ScholarPubMed
Loeber, RBurke, JDLahey, BBWinters, AZera, M. Oppositional defiant and conduct disorder: a review of the post 10 years, part I. J Am Acad Child Adolesc Psychiatry 2000;39:1468–84.CrossRefGoogle Scholar
Hechtman, LOfford, DR. Long-term outcome of disruptive disorders. Child Adolesc Psychiatry Clin North America 1994;3:379–403.CrossRefGoogle Scholar
Dhossche, DMGhani, SO. Who brings patients to the psychiatric emergency room? Psychosocial and psychiatric correlates. Gen Hosp Psychiatry 1998;20:235–40.CrossRefGoogle ScholarPubMed
Coen, RFSwanwick, GRO'Boyle, CACoakley, D. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:331–6.3.0.CO;2-J>CrossRefGoogle ScholarPubMed
Fernandes, CMBouthillette, FRaboud, JMBullock, LMoore, CFChristenson, JM, et al.Violence in the emergency department: a survey of health care workers. CMAJ 1999;161:1245–8.Google ScholarPubMed
Currier, GW. Atypical antipsychotic medications in the psychiatric emergency Service. J Clin Psychiatry 2000;61(Suppl 14):21–6.Google ScholarPubMed
Victoroff, JMack, WJNielson, KA. Psychiatric complications of dementia: impact on caregivers. Dement Geriatr Cogn Disord 1998;9:50–5.CrossRefGoogle ScholarPubMed
Yaffe, KFox, PNewcomer, RSands, LLinquist, KDane, K, et al.Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002;287:2090–7.CrossRefGoogle ScholarPubMed
Marx, MSCohen-Mansfield, JWemer, P. Agitation and falls in intitutionalized elderly persons.. J Appl Gerontol 1990;9:106–17.CrossRefGoogle ScholarPubMed
Leger, JMMoulias, RRobert, PVellas, BChapuy, PHMonfort, JC, et al.Agitation and aggressiveness among the elderly population living in nursing or retirement homes in France. Int Psychogeriatr 2002;14:405–16.CrossRefGoogle ScholarPubMed
Pappadopulos, EMaclntyre, JCCrismon, MLFindling, RLMalone, RPDerivan, A, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 2003;42:145–61.CrossRefGoogle ScholarPubMed
Rappaport, NThomas, C. Recent research findings on aggressive and violent behavior in youth: implications for clinical assessment and intervention. J Adolesc Health 2004;35(4):260–77.CrossRefGoogle ScholarPubMed
Hughes, DHKleespies, PM. Treating aggression in the psychiatric emergency Service. J Clin Psychiatry 2003;64(Suppl 4): 10–5.Google ScholarPubMed
Yildiz, ASachs, GSTurgay, A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003;20:339–46.CrossRefGoogle ScholarPubMed
Findling, RLMcNamara, NKBranicky, LASchluchter, MDLemon, EBlumer, JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000;39:509–16.CrossRefGoogle ScholarPubMed
Buitelaar, JKvan der Gaag, RJCohen-Kettenis, P,Melman, CT. A randomized controlled trial of risperidone in the treatment of aggression m hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001;62:239–48.CrossRefGoogle ScholarPubMed
Van Bellinghen, MDe Troch, C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001;11:5–13.CrossRefGoogle ScholarPubMed
Snyder, RTurgay, AAman, MBinder, CFisman, SCarroll, A, Riperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41:1026–36.CrossRefGoogle ScholarPubMed
Aman, MGDe Smedt, GDerivan, ALyons, BFindling, RL, Risperidone Disruptive Behavior Study Group. Double-blind, placebocontrolled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337–46.CrossRefGoogle Scholar
McCracken, JTMcGoogh, JShah, BCronin, PHong, DAman, MG, et al., Research Units on Pediatric Psychopharmacology Autism NetWork. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314–21.CrossRefGoogle ScholarPubMed
Shea, STurgay, ACarroll, ASchulz, MOrlik, HSmith, I, et al.Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634–e641.CrossRefGoogle ScholarPubMed
Arnold, LEVitiello, BMcDougle, CScahill, LShah, BGonzalez, NM, et al.Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical triais. J Am Acad Child Adolesc Psychiatry 2003;42:1443–50.CrossRefGoogle Scholar
Turgay, ABinder, CSnyder, RFisman, S. Long-term satety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002;110:e34.CrossRefGoogle Scholar
Findling, RLAman, MGEerdekens, MDerivan, ALyons, B, Risperidone Disruptive Behavior Study Group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004;161:677–84.CrossRefGoogle ScholarPubMed
Masi, GCosenza, AMucci, M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 2001; 11 (4):389–94.CrossRefGoogle ScholarPubMed
Gagliano, AGemmano, EPustorino, GImpallomeni, CD'Arrigo, CCalamoneri, F, et al.Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004;14(l):39–47.CrossRefGoogle ScholarPubMed
Saito, ECorrell, CUGallelli, KMcMeniman, MParikh, UHMalhotra, AK, et al.A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 2004;14(3):350–8.CrossRefGoogle ScholarPubMed
Dunbar, FKusumakar, VDaneman, DSchulz, M. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 2004;161:918–20.CrossRefGoogle ScholarPubMed
Reyes, MBuitelaar, JAugustyns, IEerdekens, M. (2004) Relapse prevention of disruptive behavior disorders in children and adolescents: a 6 month trial of risperidone versus placebo. Poster presented at the 16th World Congress of the Intenational Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP), August 22-26 2004, Berlin, Gemmany.Google Scholar
Aman, MGBinder, CTurgay, A. Risperidone effects in the presence/ absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004;14:243–54.CrossRefGoogle ScholarPubMed
Blin, OAzorin, JMBouhours, P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16:38–44.CrossRefGoogle ScholarPubMed
Segal, JBerk, MBrook, S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998;21:176–80.Google ScholarPubMed
McDougle, CJHolmes, JPCarlson, DCPelton, GHCohen, DJPrice, LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55:633–41.CrossRefGoogle ScholarPubMed
Sachs, GSGrossman, FGhaemi, SNOkamoto, ABowden, CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146–54.CrossRefGoogle ScholarPubMed
Yatham, LNGrossman, FAugustyns, IVieta, ERavindran, A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br J Psychiatry 2003;182:141–7.CrossRefGoogle ScholarPubMed
Currier, GWChou, JCFeifel, DBossie, CATurkoz, IMahmoud, RA, et al.Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004;65:386–94.CrossRefGoogle ScholarPubMed
Czobor, PVolavka, JMeibach, RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243–9.CrossRefGoogle Scholar
Citrome, LVolavka, JCzobor, PSheitman, BLindemmayer, J-PMcEvoy, J, et al.Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001 ;52(11): 1510–4.CrossRefGoogle ScholarPubMed
Volavka, JCzobor, PNolan, KSheitman, BLindenmayer, J-PCitrome, L, et al.Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004;24:225–8.CrossRefGoogle ScholarPubMed
Buckley, PFIbrahim, ZYSinger, BOrr, BDonenwirth, KBrat, PS. Aggression and schizophrenia: efficacy of risperidone. J Am Acad Psychiatry Law 1997;25(2): 173–81.Google ScholarPubMed
Beck, NCGreenfield, SRGotham, HMenditto, AAStuve, PHemme, CA. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. J Am Acad Psychiatry Law 1997;25(4):461–8.Google Scholar
Currier, GWSimpson, GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62:153–7.CrossRefGoogle ScholarPubMed
Hirose, S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001;55:161–2.CrossRefGoogle ScholarPubMed
Rocca, PMarchiaro, LCocuzza, EBogetto, F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241–4.CrossRefGoogle ScholarPubMed
Risperidone. package insert. 2005; http://www.risperdal.com/active/ janus/en_US/assets/common/company/pi/risperdal.pdf.Google Scholar
Meaney, AMSmith, SHowes, ODO'Brien, MMurray, RMO'Keane, V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;185:503–8.CrossRefGoogle Scholar
De Deyn, PPRabheru, KRasmussen, ABocksberger, JPDantzenberg, PLEriksson, S, et al.A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946–55.CrossRefGoogle ScholarPubMed
Katz, IRJeste, DVMintzer, JEClyde, CNapolitano, JBrecher, M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107–15.CrossRefGoogle ScholarPubMed
Chan, WCLam, LCChoy, CNLeung, VPLi, SWChiu, HF. A doubleblind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156–62.CrossRefGoogle Scholar
Brodaty, HAmes, DSnowdon, JWoodward, MKirwan, JClarnette, R, et al.A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134–43.CrossRefGoogle ScholarPubMed
Fontaine, CSHynan, LSKoch, KMartin-Cook, KSvetlik, DWeiner, MF. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003;64:726–30.CrossRefGoogle ScholarPubMed
Suh, GHSon, HGJu, YSJcho, KHYeon, BKShin, YM, et al.A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004;12:509–16.CrossRefGoogle ScholarPubMed
De Deyn, PPKatz, IR. Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. Int J Geriatr Psychiatry 2000;15(Suppl l):S14–22.3.0.CO;2-#>CrossRefGoogle ScholarPubMed
Jeste, DVOkamoto, ANapolitano, JKane, JMMartinez, RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150–5.CrossRefGoogle ScholarPubMed
Feldman, PDHay, LKDeberdt, WKennedy, JSHutchins, DSHay, DP, et al.Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. J Am Med Dir Assoc 2004;5:38–46.CrossRefGoogle Scholar
US Food and Drug Administration. Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. Apri 11, 2005. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm Accessed August 15.Google Scholar